Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27408098 | 0.91 | ALDH1A1 (0.31) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL23514937 | 0.85 | OPRM1 (0.31) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL15801217 | 0.84 | — | — | |
| SCHEMBL24859609 | 0.84 | — | — | |
| SCHEMBL23108654 | 0.84 | — | — | |
| SCHEMBL13069945 | 0.79 | — | — | |
| SCHEMBL16885326 | 0.79 | — | — | |
| SCHEMBL130746 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL1132327 | 0.77 | — | — | |
| SCHEMBL21030979 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230322799-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-10-12 | — | — | US | disclosed |
| US-20230322799-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-10-12 | — | — | US | disclosed |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230174521-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | MERCK & CO., INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090275599-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090253724-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | TORAY INDUSTRIES, INC. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7566724-B2 | Glycine derivative and use thereof | TORAY INDUSTRIES, INC. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-7566724-B2 | Glycine derivative and use thereof | TORAY INDUSTRIES, INC. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | TORAY INDUSTRIES, INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2009-03-19 | — | — | US | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | TORAY INDUSTRIES, INC. (JP) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | PTGES, PTGS1, PTGES2 | OPRM1 155/4885OPRD1 127/4885OPRK1 77/4885 |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | OPRM1 39/4885OPRD1 110/4885OPRK1 52/4885 |
| US-20230322799-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM2 | OPRM1 34/4885OPRD1 152/4885OPRK1 91/4885 |
| US-20090093508-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS | HRH2, TSLP, ENPEP | OPRM1 4720/4885OPRD1 3403/4885OPRK1 3797/4885 |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | OPRM1 3915/4885OPRD1 1302/4885OPRK1 2198/4885 |
| US-20080085910-A1 | Glycine Derivative and Use Thereof | GNMT, SI, SLC7A11 | OPRM1 1985/4885OPRD1 861/4885OPRK1 1087/4885 |
| US-20090275599-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS | PMP22, MGMT, ENPEP | OPRM1 4300/4885OPRD1 3069/4885OPRK1 3147/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | OPRM1 4204/4885OPRD1 3526/4885OPRK1 678/4885 |
| US-20090253724-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA | MCL1, ENPEP, SLC7A1 | OPRM1 4820/4885OPRD1 4333/4885OPRK1 4101/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | OPRM1 4580/4885OPRD1 4550/4885OPRK1 4361/4885 |
| US-11834433-B2 | Compounds | NLRP3, NOD1, PYCARD | OPRM1 1765/4885OPRD1 2214/4885OPRK1 1106/4885 |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | WEE2, WEE1, KAT2A | OPRM1 3886/4885OPRD1 4108/4885OPRK1 3614/4885 |
| US-20230174521-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | OPRM1 4517/4885OPRD1 4084/4885OPRK1 3940/4885 |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | OPRM1 91/4885OPRD1 146/4885OPRK1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.